Effect of levetiracetam monotherapy versus sodium valproate on treatment of children with generalized or focal epilepsy

Effect of levetiracetam monotherapy versus sodium valproate on treatment of children with generalized or focal epilepsy: a randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N351

Enrollment

Registered

2020-04-04

Start date

2019-07-23

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Focal epilepsy. Condition 2: Generalized epilepsy. Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset Generalized idiopathic epilepsy and epileptic syndromes

Interventions

Intervention 1: Intervention group: Levetiracetam syrup (manufactured by Lubel Daru Pharmaceutical Co.) 30 mg/kg every 12 hours for 18 months. Intervention 2: Control group: Sodium valproate syrup (ma

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: Age of 2 to 18 years, Generalized or focal epilepsy,

Exclusion criteria

Exclusion criteria: False seizures, Sustained brain injury, Acute psychosis, History of cerebral palsy, Pharmaceutic hepatitis, Liver disease, Kidney disease

Design outcomes

Primary

Measure	Time frame
Number of seizures. Timepoint: Every month. Method of measurement: By taking history.	—

Secondary

Measure	Time frame
Blood complications. Timepoint: One month after the intervention. Method of measurement: By checking cell blood count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ghazal Sami

Hamedan University of Medical Sciences

drsami.pediatrician@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026